4-[(2-Cyclohexylimino-4-methyl-1,3-thiazol-3-yl)iminomethyl]benzene-1,2,3-triol

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-[(2-Cyclohexylimino-4-methyl-1,3-thiazol-3-yl)iminomethyl]benzene-1,2,3-triol
• 化学式: C₁₇H₂₁N₃O₃S
• mdl: MFCD04606524
• 分子量: 347.4
• InChiKey: RGGFUBMUOVFZEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.411
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] INHIBITION OF MCL-1 AND/OR BFL-1/A1<br/>[FR] INHIBITION DE MCL-1 ET/OU DE BFL-1/A1
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2013142281A1

  公开（公告）日：2013-09-26

  This disclosure features compounds and pharmaceutically acceptable salts thereof that inhibit MCL-1 and/or BFL-1/A1 and compositions containing the same. This disclosure also features combinations that include one or more of the MCL-1/BFL-1/A1 inhibitor compounds described herein, or a pharmaceutically acceptable salt thereof; and one or more additional therapeutic agents (e.g., one or more chemotherapeutic agents (including small molecule and/or anti-body based chemotherapy and/or radiation); e.g., one or more therapeutic agents that modulate apoptosis; e.g., one or more therapeutic agents that bind to and inhibit anti-apoptotic proteins or modulate them indirectly; e.g., one or more therapeutic agents that bind to and inhibit, or indirectly modulate, anti-apoptotic BCL-2, BCL-XL, BCL-w, MCL-1, and/or BFL-1/A1; e.g., one or more therapeutic agents that directly bind to and inhibit anti-apoptotic BCL-2 / BCL-XL; e.g., agents such as ABT-199, ABT-263 and ABT-737; e.g., ABT-737), or (where applicable) a pharmaceutically acceptable salt of the one or more therapeutic agents (as well as compositions containing the same). Also featured are methods of using such compounds, salts, combinations, and compositions, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., diseased or damaged cells; e.g., insufficient apoptosis of diseased or damaged cells or reduced apoptosis of diseased or damaged cells)..

  本公开涉及抑制MCL-1和/或BFL-1/A1的化合物及其药用盐，以及含有这些化合物的组合物。本公开还涉及包括本文所述的一个或多个MCL-1/BFL-1/A1抑制剂化合物或其药用盐的组合物；以及一个或多个额外的治疗剂（例如，一个或多个化疗剂（包括小分子和/或抗体基础的化疗和/或放射疗法）；例如，一个或多个调节凋亡的治疗剂；例如，一个或多个结合并抑制抗凋亡蛋白或间接调节它们的治疗剂；例如，一个或多个结合并抑制或间接调节抗凋亡BCL-2、BCL-XL、BCL-w、MCL-1和/或BFL-1/A1的治疗剂；例如，一个或多个直接结合并抑制抗凋亡BCL-2 / BCL-XL的治疗剂；例如，像ABT-199、ABT-263和ABT-737这样的药物；例如，ABT-737），或（如适用）一个或多个治疗剂的药用盐（以及含有这些治疗剂的组合物）。还包括使用这些化合物、盐、组合物和组合物的方法，例如，用于治疗或预防与细胞的失调凋亡相关的疾病、紊乱和症状（例如，疾病或受损细胞；例如，疾病或受损细胞的凋亡不足或减少）。
• Tropism modified cancer terminator virus (Ad.5/3 CTV;AD.5/3-CTV-M7)
  申请人：Virginia Commonwealth University

  公开号：US10314870B2

  公开（公告）日：2019-06-11

  A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

  研究发现，一种经过滋养修饰的癌症终结者病毒（Ad.5/3-CTV；Ad.5/3-CTV-M7）具有独立于柯萨奇腺病毒受体（CAR）的感染性。Ad.5/3-CTV（Ad.5/3-CTV-M7）可单独使用，也可与其他治疗剂结合使用，如增加活性氧（ROS）产生的药物、HDAC 抑制剂、MCL-1 抑制剂和 Bcl-2 抑制剂，以治疗各种癌症，特别是恶性胶质瘤（GBM）、肾癌、前列腺癌和结直肠癌。
• Tropism modified cancer terminator virus (Ad.5/3 CTV;Ad.5/3-CTV-M7)
  申请人：VIRGINIA COMMONWEALTH UNIVERSITY

  公开号：US10744172B2

  公开（公告）日：2020-08-18

  A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.

  研究发现，一种经过滋养修饰的癌症终结者病毒（Ad.5/3-CTV；Ad.5/3-CTV-M7）具有独立于柯萨奇腺病毒受体（CAR）的感染性。Ad.5/3-CTV（Ad.5/3-CTV-M7）可单独使用，也可与其他治疗剂结合使用，如增加活性氧（ROS）产生的药物、HDAC 抑制剂、MCL-1 抑制剂和 Bcl-2 抑制剂，以治疗各种癌症，特别是恶性胶质瘤（GBM）、肾癌、前列腺癌和结直肠癌。
• INHIBITION OF MCL-1 AND/OR BFL-1/A1
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP2827864A1

  公开（公告）日：2015-01-28
• TROPISM MODIFIED CANCER TERMINATOR VIRUS (AD.5/3 CTV;AD.5/3-CTV-M7)
  申请人：Virginia Commonwealth University

  公开号：US20160008413A1

  公开（公告）日：2016-01-14

  A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.